By Kenneth Bender
(Cross posted with Pain Medicine News)
Tanezumab, an investigational monoclonal antibody that inhibits nerve growth factor (NGF), was similar to tramadol in relieving the intensity of chronic low back pain (LBP), and the 10-mg dose of tanezumab was superior to placebo in improving function at four months, in a head-to-head placebo-controlled trial.
The study results at 16 weeks and at the completion of the 56-week, phase 3 trial, prior to a 24-week follow-up period, were reported